184 related articles for article (PubMed ID: 28745522)
1. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG
COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.
Calzetta L; Rogliani P; Page C; Rinaldi B; Cazzola M; Matera MG
Pulm Pharmacol Ther; 2019 Jun; 56():39-50. PubMed ID: 30876907
[TBL] [Abstract][Full Text] [Related]
3. Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways.
Calzetta L; Rogliani P; Pistocchini E; Mattei M; Cito G; Alfonsi P; Page C; Matera MG
J Vet Pharmacol Ther; 2018 Aug; 41(4):546-554. PubMed ID: 29582435
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi.
Calzetta L; Rogliani P; Facciolo F; Rendina E; Cazzola M; Matera MG
Eur J Pharmacol; 2017 Oct; 812():147-154. PubMed ID: 28716723
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
[TBL] [Abstract][Full Text] [Related]
6. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
7. The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease.
John-Schuster G; de Kleijn S; van Wijck Y; Kremer V; Smits HH; Pieper MP; Hiemstra PS; Taube C
Pulm Pharmacol Ther; 2017 Aug; 45():210-217. PubMed ID: 28687462
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
Calzetta L; Matera MG; Cazzola M; Rogliani P
Adv Ther; 2019 Dec; 36(12):3291-3298. PubMed ID: 31654332
[TBL] [Abstract][Full Text] [Related]
9. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway.
Costa L; Roth M; Miglino N; Keglowich L; Zhong J; Lardinois D; Tamm M; Borger P
Pulm Pharmacol Ther; 2014 Feb; 27(1):29-37. PubMed ID: 24269928
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
13. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
14. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma.
Smit M; Zuidhof AB; Bos SI; Maarsingh H; Gosens R; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2014 Feb; 348(2):303-10. PubMed ID: 24307202
[TBL] [Abstract][Full Text] [Related]
15. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
17. Study Design of VESUTO
Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium/Olodaterol: A Review in COPD.
Dhillon S
Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
[TBL] [Abstract][Full Text] [Related]
19. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
20. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
